Collegium Pharmaceutical, Inc
A pharmaceutical company making medicines for pain and ADHD, including the opioid painkiller Xtampza ER (built on its DETERx abuse-deterrent technology), Belbuca, the Nucynta products, and Jornay PM, an evening-dosed ADHD stimulant. Founded in 2002 by Michael Heffernan to develop safer opioids, its name comes from the Latin "collegium," meaning a band of colleagues working together. The company even named its technology DETERx — a nod to deterring misuse, which is why its microsphere-in-capsule pain pills are hard to crush or inject.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Millennium Management LLC | 13GPassive | 5.6% | 1.82M | Aug 24, 2026 |
| Millennium Group Management LLC | 13GPassive | 5.6% | 1.82M | Aug 24, 2026 |
| Israel A. Englander | 13GPassive | 5.6% | 1.82M | Aug 24, 2026 |
| Integrated Core Strategies (US) LLC | 13GPassive | 5.4% | 1.77M | Aug 24, 2026 |
| Fuller & Thaler Asset Management, Inc. | 13GPassive | 5.03% | 1.63M | Aug 14, 2026 |
| PRINCIPAL GLOBAL INVESTORS | 13GPassive | 5% | 1.63M | Aug 5, 2026 |
| Vanguard Capital Management | 13GPassive | 5.01% | 1.63M | Jul 31, 2026 |
| JANUS HENDERSON GROUP PLC | 13GPassive | 5.8% | 1.83M | May 15, 2026 |
| Eventide Asset Management, LLC | 13G/APassive | 4.5% | 1.42M | May 15, 2026 |
| Finny Kuruvilla, M.D. Ph. D. | 13G/APassive | 4.5% | 1.42M | May 15, 2026 |